

## STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page5/line84-88	Abstract/para2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page5-6/line90-106	Abstract/para3-4
<b>Introduction</b>				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page7-8/line111-137	Introduction/para1-4
Objectives	3	State specific objectives, including any prespecified hypotheses	Page8/line137-141	Introduction/para4
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	Page8-9/line147-156	Methods/para1-2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page8-9/line147-153	Methods/para1
Participants	6	(a) <b>Cohort study</b> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <b>Case-control study</b> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <b>Cross-sectional study</b> —Give the eligibility criteria, and the sources and methods of selection of participants	Page9-10/line156-168	Methods/para2
		(b) <b>Cohort study</b> —For matched studies, give matching criteria and number of exposed and unexposed <b>Case-control study</b> —For matched studies, give matching criteria and the number of controls per case	Page9-10/line156-168	Methods/para2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page10-13/line173-227	Methods/para4-11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page10-13/line173-227	Methods/para4-11
Bias	9	Describe any efforts to address potential sources of bias	Page13/line235-239	Methods/para12
Study size	10	Explain how the study size was arrived at	Page10/line169-170	Methods/para3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page10-13/line173-227	Methods/para4-11

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page13/line230-240	Methods/para12
		(b) Describe any methods used to examine subgroups and interactions	Page13/line230-240	Methods/para12
		(c) Explain how missing data were addressed	Page13/line230-240	Methods/para12
		(d) <b>Cohort study</b> —If applicable, explain how loss to follow-up was addressed <b>Case-control study</b> —If applicable, explain how matching of cases and controls was addressed <b>Cross-sectional study</b> —If applicable, describe analytical methods taking account of sampling strategy	Page13/line230-240	Methods/para12
		(e) Describe any sensitivity analyses	Page13/line230-240	Methods/para12
<b>Results</b>				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page14/line243-244	Results/para1
		(b) Give reasons for non-participation at each stage	Page10/line169-170	Methods/para3
		(c) Consider use of a flow diagram	N/A	Described in words
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page14/line244-267	Results/para1-4
		(b) Indicate number of participants with missing data for each variable of interest	Page10/line169-170	Methods/para3
		(c) <b>Cohort study</b> —Summarise follow-up time (eg, average and total amount)	Page10/line169-170	Methods/para3
Outcome data	15*	<b>Cohort study</b> —Report numbers of outcome events or summary measures over time	Page10/line169-170	Methods/para3
		<b>Case-control study</b> —Report numbers in each exposure category, or summary measures of exposure	Page10/line169-170	Methods/para3
		<b>Cross-sectional study</b> —Report numbers of outcome events or summary measures	Page14/line250-267	Results/para2-4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page15-16/line268-291	Results/para5-7
		(b) Report category boundaries when continuous variables were categorized	Page15-16/line268-291	Results/para5-7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page15-16/line268-291	Results/para5-7
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page14/line250-267	Results/para2-4
<b>Discussion</b>				
Key results	18	Summarise key results with reference to study objectives	Page16/line294-301	Discussion/para1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page18/line330-341	Discussion/para4

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page17-18/line318-329	Discussion/para3
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page18/line337-341	Discussion/para4
<b>Other information</b>				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page20/line359-363	Acknowledgments/para1 Financial disclosure/para1

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

Article information: <http://dx.doi.org/10.21037/atm-20-6957>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.